Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (33)
2024
-
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Bone Marrow Transplantation
-
Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results
HemaSphere
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
Blood Advances, Vol. 6, Núm. 18, pp. 5395-5402
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival
International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894
-
Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study (Leukemia, (2020), 34, 9, (2333-2341), 10.1038/s41375-020-0758-4)
Leukemia
2020
-
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols
European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
-
Novel DNMT3A germline variant in a patient with multiple paragangliomas and papillary thyroid carcinoma
Cancers, Vol. 12, Núm. 11, pp. 1-12
-
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Leukemia, Vol. 34, Núm. 9, pp. 2333-2341
2019
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
-
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry
Leukemia and Lymphoma, Vol. 60, Núm. 11, pp. 2720-2732
-
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients
British Journal of Haematology, Vol. 186, Núm. 2, pp. 263-268